Effect of IL-1 on the hydrolysis of the tumor antigen epitope gp100280-288 by fibroblast-expressed enzymes

Cytokine

Volumn 36, Issue 3-4, 2006, Pages 189-198

  Cavazza, Antonella ^a   Marini, Mario ^a   Spagnoli, Giulio C ^b   Giorgio Roda, L ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Epitopes; Fibroblasts; IL 1; Proteolysis; Vaccine

Indexed keywords

AMINO ACID; EPITOPE; GLYCOPROTEIN GP 100; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1; TUMOR ANTIGEN; TYROSYLLEUCYLGLUTAMYLPROLYLGLYCYLPROLYLVALYLTHREONYLALANINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CULTURE; CULTURE MEDIUM; ENZYME SUBSTRATE COMPLEX; FIBROBLAST; HUMAN; HUMAN CELL; HYDROLYSIS; IMMUNIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REACTION ANALYSIS;

AMINO ACIDS; CHROMATOGRAPHY, LIQUID; CULTURE MEDIA, SERUM-FREE; FIBROBLASTS; HUMANS; HYDROLYSIS; INTERLEUKIN-1; KINETICS; MEMBRANE GLYCOPROTEINS; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES;

EID: 33847025260     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2006.12.004     Document Type: Article

References (49)

1. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
2. Renkvist N., Castelli C., Robbins P.F., and Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50 (2001) 3-15
3. Lage A., Perez R., and Fernandez L.E. Therapeutic cancer vaccines: at midway between immunology and pharmacology. Curr Cancer Drug Targets 5 (2005) 611-627
4. Lollini P.L., Cavallo F., Nanni P., and Forni G. Vaccines for tumour prevention. Nat Rev Cancer 6 (2006) 204-216
5. Parmiani G., Castelli C., Dalerba P., Mortarini R., Rivoltini L., Marincola F.M., et al. Cancer immunotherapy with peptide based vaccines: what have we achieved? Where are we going?. J Natl Cancer Inst 94 (2002) 805-818
6. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4 (1998) 328-332
7. Linette G.P., Zhang D., Hodi S., Jonasch E.P., Longerich S., Stowell C.P., et al. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin Cancer Res 11 (2005) 7692-7699
8. Germain R.N., and Hendrix L.R. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature 353 (1991) 134-139
9. Yu Z., Theoret M.R., Touloukian C.E., Surman D.R., Garman S.C., Feigenbaum L., et al. Poor immunogenicity of self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest 114 (2004) 551-559
10. van der Bruggen P., and Van den Eynde B. Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol 18 (2006) 98-104
11. Lee V.H.L. Enzymatic barriers to peptide and protein absorption. CRC Crit Rev Therapy Drug Carrier Syst. 5 (1988) 69-97
12. Powell M.F., Grey H., Gaeta F., Sette A., and Colon S. Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J Pharmacol Sci 81 (1992) 731-735
13. Adessi C., and Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem 9 (2002) 963-978
14. Caughey G.H., Lazarus S.C., Viro N.F., Gold W.M., and Nadel J.A. Tryptase and chymase: comparison of extraction and release in two dog mastocytoma lines. Immunology 63 (1988) 339-344
15. Boderke P., Merkle H.P., Cullander C., Ponec M., and Bodde H. Localization of aminopeptidase activity in freshly excised human skin: direct visualization by confocal laser scanning microscopy. J Invest Dermatol 108 (1997) 83-86
16. Cochrane D.E., Carraway R.E., Boucher W., and Feldberg R.S. Rapid degradation of neurotensin by stimulated rat mast cells. Peptides 12 (1991) 1187-1194
17. Marini M., Urbani A., Bongiorno L., and Roda L.G. Soluble enkephalin-degrading enzymes released by lymphomic and erythroleukaemic cell lines. Neurochem Res 17 (1992) 1155-1161
18. Widmann C., Maryanski J.L., Romero P., and Corradin G. Differential stability of antigenic MHC class-I restricted synthetic peptides. J Immunol 147 (1991) 3745-3751
19. Amoscato A.A., Prenovitz D.A., and Lotze M.T. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J Immunol 161 (1998) 4023-4032
20. 280-288 by membrane-associated and soluble enzymes expressed by immature and mature dendritic cells. Clin Immunol 111 (2004) 252-261
21. 280-288 by fibroblasts-associated enzymes abolishes specific immunorecognition. Biochim Biophys Acta 1671 (2004) 59-69
22. Haro I., and Gomara M.J. Design of synthetic peptidic constructs for the vaccine development against viral infections. Curr Protein Pept Sci 5 (2004) 425-433
23. Dredge K., Marriott J.B., Todryk S.M., and Dalgeish A.G. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother 51 (2002) 521-531
24. Murtaugh M.P., and Foss D.L. Inflammatory cytokines and antigen presenting cell activation. Vet Immunol Immunopathol 87 (2002) 109-121
25. Reis e Susa C. Toll-like receptors and dendritic cells: for whom the bug tolls. Semin Immunol 16 (2004) 27-34
26. Shimizu K., Fields R.C., Giedlin M., and Mule J.J. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA 96 (1999) 2268-2273
27. Thyphronitis G., and Kuotsilieris M. Boosting immune response: an alternative combination therapy for cancer patients. Anticancer Res 24 (2004) 2443-2454
28. Dayer J.M., de Rochemonteix B., Burrus B., Demczuk S., and Dinarello C.A. Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human sinovial cells. J Clin Invest 77 (1986) 645-648
29. Sorrell J.M., Brinon L., Baber M., and Caplan A.I. Cytokines and glucocorticoids differentially regulate APN/CD13 and DPPIV/CD26 enzyme activities in cultured human dermal fibroblasts. Arch Dermatol Res 295 (2003) 160-168
30. Van Damme J., Struif S., and Opdenakker G. Chemokine-protease interactions in cancer. Semin Cancer Biol 14 (2004) 201-208
31. Circolo A., Welgus H.G., Pierce G.F., Kramer J., and Strunk R.C. Differential regulation of the expression of proteinases/antiproteinases in fibroblasts. J Biol Chem 266 (1991) 12283-12288
32. Cox S.W., Eley B.M., Kiili M., Asikainen A., Tervahartiala T., and Sorsa T. Collagen degradation by interleukin-1-beta-stimulated gingival fibroblasts is accompanied by release and activation of multiple matrix metalloproteinases and cysteine proteinases. Oral Diseases 12 (2006) 34-40
33. Han Y.P., Downey S., and Garner W.L. Interleukin-1α induced proteolytic activation of metalloproteinase-9 by human skin. Surgery 138 (2005) 932-939
34. Han R., and Smith T.J. Induction by IL-1β of tissue inhibitor of metalloproteinase-1 in human orbital fibroblasts: modulation of gene promoter activity by IL-4 and IFN-γ. J Immunol 174 (2005) 3072-3079
35. Kunij R., Nemoto E., Kanaya S., Tsubahara T., and Shimauchi H. Expression of CD13/aminopeptidase N on human gingival fibroblasts and up-regulation upon stimulation with interleukin-4 and interleukin-13. J Periodont Res 40 (2005) 138-146
36. Atkins M.B. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 12 (2006) 2353s-2358s
37. Yan L., Anderson G.M., DeWitte M., and Nakada M.T. Therapeutical potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer 42 (2006) 793-802
38. van Kempen L.C., de Visser K.E., and Coussens L.M. Inflammation, proteases and cancer. Eur J Cancer 42 (2006) 728-734
39. Bakker A.B.H., Scherurs M.W.J., de Boer A.J., Kawakami Y., Rosenberg S.A., Adema G.J., and Frigdor C.G. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179 (1994) 1005-1009
40. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., and Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139 (1991) 271-279
41. Van Ranst M., Norga K., Masure S., Proost P., Vandekerckhove F., Auwerx J., et al. The cytokine-protease connection: identification of a 96-kD THP-1 gelatinase and regulation by interleukin-1 and cytokine inducers. Cytokine 3 (1991) 231-239
42. Nemoto E., Sugawara S., Takada H., Shoji S., and Hiroshi H. Increase of CD26/dipeptidyl peptidase IV expression on human gingival fibroblasts upon stimulation with cytokines and bacterial components. Infect Immun 67 (1999) 6225-6233
43. Saison M., Verlinden J., Van Leuven F., Cassiman J.J., and Van den Berghe H. Identification of cell surface dipeptidylpeptidase IV EC-34145 in human fibroblasts. Biochem J 216 (1983) 177-184
44. Sato T., Ito A., and Mori Y. Interleukin 6 enhances the production of tissue inhibitors of metalloproteinases (TIMP) but not that of matrix metalloproteinases by human fibroblasts. Biochim Biophys Res Commmun 170 (1990) 824-829
45. Shingu M., Nagai Y., Isayama T., Naouno T., Nobunaga M., and Nagay Y. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 94 (1993) 145-149
46. Nagase H., and Woessner J.F. Matrix metalloproteinases. J Biol Chem 274 (1999) 21491-21494
47. Roda L.G., Bongiorno L., Trani E., Urbani A., and Marini M. Positive and negative immunomodulation by opioid peptides. Int J Immunopharmacol 18 (1996) 1-16
48. Sette A., Sidney J., del Guercio M.F., Southwood S., Ruppert J., Dahlberg C., et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol 31 (1994) 813-822
49. Chapiro J., Claverol S., Piette F., Ma W., Stroobant V., Guillaume B., et al. Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J Immunol 176 (2006) 1053-1061